Please select the outcome measures that correspond to the clinical trial below.
Title: An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life
Brief Summary: Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life.

Secondary objectives: To describe the safety profile of a first dose of ProQuad® manufactured with rHA when administered to children in their second year of life.


Options:
A: Frequencies of Glycoprotein E (gE)-Specific Cluster of Differentiation 4 (CD4) / CD8 T Cells With at Least Two Antigen-specific Cytokines: Interferon Gamma (IFN-γ), Interleukin 2 (IL-2), Tumor Necrosis Factor Alpha (TNF-α), CD 40 Ligand (CD40L). (At Month 30 after the first vaccination.); Frequencies of Varicella Zoster Virus (VZV)-Specific CD4 / CD8 T Cells With at Least Two Antigen-specific Cytokines (IFN-γ, IL-2, TNF-α, CD40L). (At Month 30 after the first vaccination); Frequencies of Glycoprotein E (gE)-Specific CD4 / CD8 T Cells With at Least Two Antigen-specific Cytokines (IFN-γ, IL-2, TNF-α, CD40L). (At Month 42 after the first vaccination); Frequencies of Varicella Zoster Virus (VZV)-Specific CD4 / CD8 T Cells With at Least Two Antigen-specific Cytokines (IFN-γ, IL-2, TNF-α, CD40L). (At Month 42 after the first vaccination)
B: Number of Subjects With Seroresponse for Antibodies to Varicella Virus (VZV) (At Day 42 after vaccination); Concentration of Antibodies to Varicella Virus (VZV) (At Day 42 after vaccination); Number of Subjects With Seroresponse for Antibodies to Mumps Virus (At Day 42 after vaccination); Number of Subjects With Seroresponse for Antibodies to Measles Virus (At Day 42 after vaccination); Number of Subjects With Seroresponse for Antibodies to Rubella Virus (At Day 42 after vaccination); Concentration of Antibodies to Hepatitis A Virus (HAV) (At Day 42 after vaccination); Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (At Day 42 after vaccination)
C: Reduce burden of illness due to herpes zoster (HZ) (Incidence of postherpetic neuralgia (PHN), where PHN is defined as HZ-associated pain greater than or equal to 3 persisting or appearing more than 30 days after the onset of the HZ rash)
D: Percentage of Participants Experiencing an Adverse Event (AE) After ProQuad® Dose 2 (Up to Day 70 (up to 28 days after ProQuad® Dose 2)); Percentage of Participants Experiencing a Vaccine-related AE After ProQuad® Dose 2 (Up to Day 70 (up to 28 days after ProQuad® Dose 2)); Percentage of Participants Experiencing a Solicited Injection-site AE After ProQuad® Dose 2 (Up to Day 46 (for 4 days following ProQuad® Dose 2)); Percentage of Participants Experiencing a Unsolicited Injection-site AE After ProQuad® Dose 2 (Up to Day 70 (up to 28 days after ProQuad® Dose 2)); Percentage of Participants Experiencing a Injection-site Rash of Interest AE After ProQuad® Dose 2 (Up to Day 70 (up to 28 days after ProQuad® Dose 2)); Percentage of Participants Experiencing a Systemic AE After ProQuad® Dose 2 (Up to Day 70 (up to 28 days after ProQuad® Dose 2)); Percentage of Participants Experiencing a Vaccine-related Systemic AE After ProQuad® Dose 2 (Up to Day 70 (up to 28 days after ProQuad® Dose 2)); Percentage of Participants Experiencing a Non-injection-site Rash of Interest AE After ProQuad® Dose 2 (Up to Day 70 (up to 28 days after ProQuad® Dose 2)); Percentage of Participants Experiencing a Mumps-like Illness After ProQuad® Dose 2 (Up to Day 70 (up to 28 days after ProQuad® Dose 2)); Percentage of Participants Experiencing a Serious AE (SAE) After ProQuad® Dose 2 (Up to Day 84 (up to 42 days after ProQuad® Dose 2)); Percentage of Participants Experiencing a Vaccine-related SAE After ProQuad® Dose 2 (Up to Day 84 (up to 42 days after ProQuad® Dose 2))

Answer: D